Species considerations in hybridoma technology — rabbits vs. mice Which statement correctly describes rabbits and mice in the context of myelomas and antibody synthesis used for monoclonal antibody production?

Introduction / Context:
Classical hybridoma technology relies on fusing antibody-producing B cells with immortal myeloma partners. Species differences have historically shaped which animals are used for monoclonal antibody generation and why mouse systems dominated early monoclonal antibody development.

Given Data / Assumptions:

• Myeloma cell lines are required as fusion partners to confer immortality.
• Mice have well-established myeloma lines (e.g., SP2/0, NS0).
• Rabbits are excellent for generating high-affinity antibodies, but classical rabbit myeloma lines were historically lacking.

Concept / Approach:
Because mice have robust myeloma lines and produce antibodies naturally, they became the standard species for hybridoma production. Rabbits produce antibodies too, but the absence (historically) of stable rabbit myeloma lines limited classic rabbit hybridomas. Modern methods (phage display, transgenic mice, rabbit B-cell immortalization) exist, but the traditional teaching point remains: mouse myelomas are widely available; rabbit myelomas are not.

Step-by-Step Solution:

Verification / Alternative check:
Hybridoma protocols commonly specify mouse myeloma cell lines; rabbit monoclonals typically use alternative technologies rather than classic myeloma fusion.

Why Other Options Are Wrong:

• Claims that mice cannot synthesize antibodies are false.
• Statements that rabbits make myelomas in the classical sense are historically inaccurate.
• Equivalence of rabbit and mouse myelomas is incorrect.

Common Pitfalls:
Confusing antigen production (antibodies) with availability of immortal myeloma fusion partners; the issue is the latter.

Final Answer:
Rabbits do not make myelomas whereas mice are able to synthesize antibodies